Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial

Journal of Thoracic Oncology

Volumn 10, Issue 9, 2015, Pages 1349-1356

  Zhao, Yang ^a   Dai, Zhijun ^a   Min, Weili ^a   Sui, Xin ^b   Kang, Huafeng ^a   Zhang, Yunfeng ^b   Ren, Hong ^b   Wang, Xijing ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Paclitaxel; Perioperative chemotherapy; Phase III; Preoperative chemotherapy; Squamous cell carcinoma of esophagus

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS SURGERY; FEMALE; GRANULOCYTOPENIA; HEMOGLOBINOPATHY; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PREOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT RESPONSE; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 84940103173     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000612     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A, Cancer statistics, 2014. CA Cancer J Clin 2014 64 9 29
2. Siegel R, Naishadham D, Jemal A, Cancer statistics, 2013. CA Cancer J Clin 2013 63 11 30
3. Siegel R, Naishadham D, Jemal A, Cancer statistics, 2012. CA Cancer J Clin 2012 62 10 29
4. Liu JF, Wang QZ, Hou J, Surgical treatment for cancer of the oesophagus and gastric cardia in Hebei, China. Br J Surg 2004 91 90 98
5. Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M, Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol 2012 23 1095 1103
6. Ando N, Kato H, Igaki H, A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012 19 68 74
7. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009 27 5062 5067
8. Ando N, Iizuka T, Ide H, Japan Clinical Oncology Group Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 2003 21 4592 4596
9. Zhang J, Chen HQ, Zhang YW, Xiang JQ, Adjuvant chemotherapy in oesophageal cancer: a meta-analysis and experience from the Shanghai Cancer Hospital. J Int Med Res 2008 36 875 882
10. Ku GY, Ilson DH, Adjuvant (postoperative) therapy for esophageal cancer. Thorac Surg Clin 2013 23 525 533
11. Ychou M, Boige V, Pignon JP, Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011 29 1715 1721
12. Cunningham D, Allum WH, Stenning SP, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006 355 11 20
13. Okines A, Sharma B, Cunningham D, Perioperative management of esophageal cancer. Nat Rev Clin Oncol 2010 7 231 238
14. Kelsen DP, Winter KA, Gunderson LL, Radiation Therapy Oncology Group; USA Intergroup Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007 25 3719 3725
15. Kelsen DP, Ginsberg R, Pajak TF, Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998 339 1979 1984
16. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials Group Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007 8 226 234
17. Fiorica F, Di Bona D, Schepis F, Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004 53 925 930
18. Ilson DH, Ajani J, Bhalla K, Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998 16 1826 1834
19. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP, Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994 86 1086 1091
20. Ajani JA, Ilson DH, Kelsen DP, Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 1996 23 5 Suppl 12 55 58
21. Mizota A, Shitara K, Kondo C, A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology 2011 81 237 242
22. Trotti A, Colevas AD, Setser A, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003 13 176 181
23. Party MOCW Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002 359 1727 1733
24. Sjoquist KM, Burmeister BH, Smithers BM, Australasian Gastro-Intestinal Trials Group Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011 12 681 692
25. Boonstra JJ, Kok TC, Wijnhoven BP, Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 2011 11 181
26. Ando N, Iizuka T, Kakegawa T, A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997 114 205 209
27. Iizuka T, Kakegawa T, Ide H, Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992 22 172 176
28. Greil R, Stein HJ, Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol 2007 8 189 190
29. Munro AJ, Oesophageal cancer: a view over overviews. Lancet 2004 364 566 568
30. Pennathur A, Gibson MK, Jobe BA, Luketich JD, Oesophageal carcinoma. Lancet 2013 381 400 412
31. Rowinsky EK, Donehower RC, Paclitaxel (taxol). N Engl J Med 1995 332 1004 1014
32. Polee MB, Tilanus HW, Eskens FA, Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol 2003 14 1253 1257
33. Yun T, Han JY, Lee JS, Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer 2011 11 385
34. Huang J, Zhou Y, Zhang H, A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol 2013 30 343
35. Ancona E, Ruol A, Santi S, Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001 91 2165 2174
36. Berger AC, Farma J, Scott WJ, Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005 23 4330 4337
37. Kleinberg L, Forastiere AA, Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007 25 4110 4117
38. Adelstein DJ, Rice TW, Rybicki LA, Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000 18 2032 2039
39. van Hagen P, Hulshof MC, van Lanschot JJ, CROSS Group Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012 366 2074 2084
40. van Heijl M, van Lanschot JJ, Koppert LB, Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008 8 21